UiPath (NYSE:PATH) Shares Up 1.1%

Shares of UiPath Inc. (NYSE:PATH) shot up 1.1% during mid-day trading on Tuesday . The company traded as high as $12.38 and last traded at $12.37. 1,044,824 shares were traded during mid-day trading, a decline of 89% from the average session volume of 9,878,062 shares. The stock had previously closed at $12.24.

Analyst Ratings Changes

A number of research firms have issued reports on PATH. Morgan Stanley cut their target price on UiPath from $25.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 30th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research note on Thursday, May 30th. Barclays cut their price objective on shares of UiPath from $25.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 30th. Mizuho cut their price objective on shares of UiPath from $25.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 30th. Finally, Canaccord Genuity Group lowered their target price on UiPath from $30.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, May 31st. Sixteen investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, UiPath presently has a consensus rating of “Hold” and a consensus target price of $18.06.

UiPath Stock Performance

The company has a 50 day simple moving average of $13.46 and a two-hundred day simple moving average of $19.18. The company has a market cap of $6.99 billion, a PE ratio of -76.22 and a beta of 0.86.

UiPath (NYSE:PATH) last released its earnings results on Wednesday, May 29th. The healthcare company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). UiPath had a negative return on equity of 2.97% and a negative net margin of 6.41%. The company had revenue of $335.11 million for the quarter, compared to analysts’ expectations of $332.84 million. As a group, analysts expect that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $19.79, for a total transaction of $791,600.00. Following the completion of the sale, the chief financial officer now directly owns 946,848 shares in the company, valued at approximately $18,738,121.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 22.37% of the company’s stock.

Institutional Investors Weigh In On UiPath

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC bought a new stake in shares of UiPath in the fourth quarter valued at approximately $25,000. HighMark Wealth Management LLC bought a new stake in shares of UiPath in the fourth quarter valued at approximately $27,000. ORG Partners LLC raised its stake in shares of UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares in the last quarter. Cypress Capital Management LLC WY acquired a new position in shares of UiPath in the fourth quarter valued at $29,000. Finally, GAMMA Investing LLC acquired a new position in shares of UiPath in the fourth quarter valued at $36,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.